+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)


Pseudomonas Aeruginosa Infection Treatment Market - Growth, Trends, and Forecasts (2020 - 2025)

  • ID: 4896269
  • Report
  • June 2020
  • Region: Global
  • 112 pages
  • Mordor Intelligence


  • AstraZeneca plc
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Pfizer, Inc.
  • MORE
Pseudomonas Aeruginosa is a common encapsulated, Gram-negative, rod-shaped bacterium that can cause disease in humans. P. aeruginosa is a multidrug-resistant pathogen recognized for its ubiquity, its intrinsically advanced antibiotic resistance mechanisms, and its association with serious illnesses including hospital-acquired infections such as ventilator-associated pneumonia and various sepsis syndromes.

The prevalence of Hospital Acquired Infections have increased in recent years. As pseudomonas aeruginosa infection is one of the common infections in hospital facility, probability of being diagnosed with Pseudomonas Aeruginosa infection is high. This has led increase in research and development in understanding P. aeruginosa. As a result, many drugs are in pipeline for the treatment of this infection. These factors have helped the growth of the market and are expected to help in the future as well.

However, as stated earlier, P. aeruginosa shows to the ability of drug resistance. As a result, many drug developers, who have limited funds are dissuaded from the market. This factor has been hindering the market growth.

Key Market Trends

Combination Therapy is expected to Dominate the Market

Combination therapy for treatment of P. aeruginosa is administered due to different considerations. First, to cover the known or suspected pathogen while results of identification and susceptibility testing are pending, second, to avoid emergence of resistance during treatment and third, due to possible synergistic activity resulting in better clinical outcome.

Research was published by Nicole Fosse et al., in PLoS One Journal 2018. During the study period, patients with P. aeruginosa bloodstream infections (BSI) were identified. Combination therapy was administered in 42.8% and remaining 57.2% were treated with monotherapy. The research concluded that mortality was lower in patients receiving definite combination therapy, as compared to monotherapy and combination therapy showed good results.

Due to the benefits of combination therapy over monotherapy, this market is expected to increase in the forecast period.

North America is Expected to Dominate the Market

As per a report by the Agency for Healthcare Research and Quality, 2019, approximately 1 of every 25 hospitalized patients in the United States have a hospital-acquired infection (HAI). This ratio translated to nearly 650,000 patients contract one of these infections annually. According to the American Association for the Advancement of Science, proportion of patients with a hospital-acquired infection was 7.9% in 2017, in Canadian Hospitals. As pseudomonas aeruginosa infection is common, the probability of this infection is still prevalent in these countries.

However, the United States (US) and Canada have a developed and well-structured health care system. These systems also encourage research and development. These policies encourage global players to enter the US and Canada. As a result, these countries enjoy the presence of many global market players. As high and increasing demand is met by the presence of global players in the region, the market is further expected to increase.

Competitive Landscape

Majority of the Pseudomonas Aeruginosa Infection Treatment drugs and therapies are being manufactured by the global key players. Market leaders with more funds for research and better distribution system have established their position in the market. Moreover, Asia-pacific is witnessing an emergence of some small players due to the rise of awareness. This has also helped the market grow.

Reasons to Purchase this report:
  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

This report will be delivered within 2 business days.
Note: Product cover images may vary from those shown


  • AstraZeneca plc
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Pfizer, Inc.
  • MORE
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study



4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Prevalence of Hospital Acquired Infections
4.2.2 Investment in Research and Drug Discovery for Pseudomonas Aeruginosa
4.3 Market Restraints
4.3.1 Drug Resistance Ability of Pseudomonas Aeruginosa
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry

5.1 By Treatment
5.1.1 Monotherapy
5.1.2 Combination Therapy
5.2 By Route of Administration
5.2.1 Nasal
5.2.2 Oral
5.2.3 Intravenous
5.3 Geography
5.3.1 North America United States Canada Mexico
5.3.2 Europe Germany United Kingdom France Italy Spain Rest of Europe
5.3.3 Asia-Pacific China Japan India Australia South Korea Rest of Asia-Pacific
5.3.4 Middle-East and Africa GCC South Africa Rest of Middle-East and Africa
5.3.5 South America Brazil Argentina Rest of South America

6.1 Company Profiles
6.1.1 AbbVie Inc. (Allergan plc)
6.1.2 Teva Pharmaceutical Industries Ltd.
6.1.3 Pfizer, Inc.
6.1.4 Lupin Pharmaceuticals, Inc.
6.1.5 AstraZeneca plc
6.1.6 Merck & Co., Inc.
6.1.7 Bristol Myers Squibb Company
6.1.8 Johnson & Johnson

Note: Product cover images may vary from those shown
  • AbbVie Inc. (Allergan plc)
  • Teva Pharmaceutical Industries Ltd.
  • Pfizer, Inc.
  • Lupin Pharmaceuticals, Inc.
  • AstraZeneca plc
  • Merck & Co., Inc.
  • Bristol Myers Squibb Company
  • Johnson & Johnson
Note: Product cover images may vary from those shown